Clinical trials: Aripiprazole
Irritability Associated With Autistic Disorder
Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder
The purpose of this study is to determine whether pediatric participants with irritability associated with autistic disorder who have responded to aripiprazole treatment will experience a relapse significantly later when…
- Trial name
- NCT01227668
- Testing
- Aripiprazole
- Where
- 38 sites in United States
- Volunteers
- 215 people
- Sponsor
- Bristol-Myers Squibb
Pharmacokinetics, Cytochrome P-450 CYP2D6
Open Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Aripiprazole When Coadministered To Healthy Subjects
The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine Sustained Release (SR) on the pharmacokinetics of Aripiprazole when coadministered to healthy adult subjects.
- Conditions
- Pharmacokinetics, Cytochrome P-450 CYP2D6, CYP3A4 Protein, Human
- Trial name
- NCT01188668
- Testing
- Aripiprazole, Aripiprazole + desvenlafaxine succinate sustained release
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Pfizer
Aggression, Attention Deficit-Hyperactivity
Metabolic Effects of Antipsychotics in Children
The project aims to describe and compare the outcome of 12 weeks of prospective, randomized treatment with olanzapine, risperidone or aripiprazole on insulin action in skeletal muscle, liver and adipose tissue, abdominal fat…
- Conditions
- Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders
- Trial name
- MEAC (NCT00205699)
- Testing
- risperidone, olanzapine, aripiprazole
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- Washington University School of Medicine
Schizophrenia, Bipolar Disorder
Early Detection and Intervention for the Prevention of Psychosis
EDIPP is a multisite trial of early identification and intervention to prevent the onset of psychosis in adolescents and young adults, carried out at six sites across the United States.
- Conditions
- Schizophrenia, Bipolar Disorder, Depression, Psychotic Disorders
- Trial name
- EDIPP (NCT00531518)
- Testing
- aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine, Psychoeducational multifamily group treatment, Supported employment and education
- Where
- 6 sites in United States
- Volunteers
- 292 people
- Sponsor
- MaineHealth
Attention Deficit Hyperactivity Disorder
Treatment of Children With ADHD Who do Not Fully Respond to Stimulants
The purpose of this pilot is to initiate a program of research into the development of effective medication techniques to treat those children with ADHD who are referred because they are "partial" or "non-responders" to standard…
- Trial name
- TREAT (NCT00279409)
- Testing
- aripiprazole, Sugar pill
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- New York State Psychiatric Institute
Bipolar Disorder, Alcoholism
Aripiprazole for Bipolar Disorder and Alcohol Use Disorder
The investigators will conduct a 12-week, randomized, double-blind, parallel-group, placebo-controlled study of aripiprazole in 132 persons with Alcohol Use Disorder (AUD) and bipolar I or II disorder, currently depressed or…
- Conditions
- Bipolar Disorder, Alcoholism, Alcohol Abuse
- Trial name
- NCT02918370
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Texas Southwestern Medical Center
Schizophrenia
An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of extended-release (ER) paliperidone compared to aripiprazole (atypical antipsychotic) in symptomatic (having symptoms) adolescent participants with schizophrenia…
- Trial name
- NCT01009047
- Testing
- Paliperidone extended release (ER), Aripiprazole
- Where
- 41 sites in United States, India and 5 more
- Volunteers
- 228 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia, Schizoaffective Disorder
Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder
The study will compare the effectiveness of antipsychotic medications for patients with schizophrenia or schizoaffective disorder for whom a medication change may be indicated because of an increased risk of cardiovascular…
- Trial name
- CAMP (NCT00423878)
- Testing
- Risperidone, Olanzapine, Quetiapine
- Where
- 28 sites in United States
- Volunteers
- 215 people
- Sponsor
- National Institute of Mental Health (NIMH)
Tourette's Disorder (TD)
Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder
To evaluate the long-term efficacy of oral aripiprazole in pediatric participants for the treatment of Tourette's Disorder (TD).
- Trial name
- NCT03661983
- Testing
- Aripiprazole
- Where
- 42 sites in United States, Canada and 1 more
- Volunteers
- 36 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Type 2 Diabetes Mellitus
Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole
This proposal aims to use well-validated methodologies such as dual energy x-ray absorptiometry (DEXA), frequently sampled oral glucose tolerance tests (fsOGTTs), and hyperinsulinemic euglycemic clamps to characterize the…
- Trial name
- BMS (NCT00205660)
- Testing
- Stayers, Switchers
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia, Major Depressive Disorder
Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System
This study will assess the helpfulness of the integrated call center in optimizing use of the Digital Medicine System in adult subjects with Schizophrenia, Major Depressive Disorder, or Bipolar Disorder taking oral aripiprazole.
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Trial name
- NCT02722967
- Testing
- Aripiprazole + IEM (Ingestible Event Marker)
- Where
- 4 sites in United States
- Volunteers
- 49 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Aripiprazole Once-monthly in Patients With Schizophrenia
To obtain information on the safety, tolerability and effectiveness of aripiprazole once-monthly in a manner consistent with its intended use in everyday clinical practice in patients with schizophrenia who completed Study 14724A…
- Trial name
- NCT01959035
- Testing
- Aripiprazole once-monthly
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- H. Lundbeck A/S
Major Depressive Disorder
Aripiprazole Augmentation of SSRI Therapy in Treatment Refractory Depression
Our target population will have been adequately treated with one of three selective serotonin reuptake inhibitors (SSRIs; escitalopram, citalopram, or sertraline) for at least 8-12 weeks and continue to experience symptoms of…
- Trial name
- NCT00608543
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Texas Southwestern Medical Center
Bipolar Disorder Mania
Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder
The purpose of the study is to determine whether aripiprazole provides additional clinical benefit to patients with Bipolar I disorder when combined with lithium or valproate over 12 weeks.
- Trial name
- NCT00665366
- Testing
- Aripiprazole, Lithium, Valproate
- Where
- 73 sites in Austria, Czechia and 11 more
- Volunteers
- 493 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia
To assess the pharmacokinetics and safety of aripiprazole intra-muscular (IM) depot formulation in patients with schizophrenia after repeated administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in…
- Trial name
- NCT02220712
- Testing
- OPC-14597 IMD
- Where
- 5 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Behavioral Symptoms, Autistic Disorder
Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)
This study will compare the effectiveness (how well the drug works) of aripiprazole with placebo (fixed dose) in reducing serious behavioral problems in children and adolescents with a diagnosis of autistic disorder (AD).
- Trial name
- NCT00337571
- Testing
- Aripiprazole
- Where
- 31 sites in United States
- Volunteers
- 218 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia
The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.
- Trial name
- NCT01469039
- Testing
- ALKS 9072
- Where
- 84 sites in United States, Bulgaria and 6 more
- Volunteers
- 623 people
- Sponsor
- Alkermes, Inc.
Tourette's Disorder
ABF Tourette's Disorder Post Marketing Surveillance Study
This is a Post-Marketing Surveillance study of Abilify® tablets in accordance with Korean regulations on New Drug Re-examination (i.e. New Drug Re-examination Standards: KFDA Notification No. 2010-94 dated 27 December 2010).
- Trial name
- NCT01795105
- Where
- 4 sites in South Korea
- Volunteers
- 692 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Healthy Male Adults
Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults
To investigate the bioequivalence of aripiprazole between administration of one ASC-01 tablet (aripiprazole 3 mg/sertraline 100 mg combination drug) and concomitant administration of one aripiprazole 3-mg tablet and two…
- Trial name
- NCT03342963
- Testing
- ASC-01, Aripiprazole and sertraline
- Where
- Japan
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia, Bipolar 1 Disorder
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
The primary objective of this pragmatic clinical trial (Main Study) was to assess the difference between all-cause hospitalizations in participants using Abilify MyCite versus virtual matched controls.
- Conditions
- Schizophrenia, Bipolar 1 Disorder, Major Depressive Disorder
- Trial name
- NCT03643159
- Testing
- Abilify MyCite - Digital Medicine System, Aripiprazole or other oral antipsychotics
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.